Healthpeak Properties, Inc. (DOC): price, analyst ratings, earnings and fundamentals
Updated 16 October 2026, 06:50 ET
Healthpeak Properties, Inc. (DOC) closed at $18.96 on 15 October 2026, up 1.2%. The stock is down 6.8% over one month and up 4.5% over one year. It trades 17.4% below its 52-week high of $22.95. Analysts recorded 9 actions in the last 90 days; the median price target of $22 is 16.0% above the last close. The company last reported on 4 August 2026 for Q2 2026: EPS of $0.46 against an estimate of $0.44, a beat of 4.5%, on revenue of $771.6 million.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open DOC in FundSpec.
Analyst ratings
Over the last 90 days FundSpec recorded 9 analyst actions on DOC from 8 firms: 8 maintained or reiterated a view and 1 initiation. Price targets were 5 raised and 4 lowered. The most recent targets from 14 firms range from $20 to $24, with a median of $22, 16.0% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 13 Oct 2026 | UBS | Maintains Neutral | $21.50 to $20.00 |
| 13 Oct 2026 | Barclays | Maintains Equal-Weight | $24.00 to $21.00 |
| 21 Sep 2026 | Evercore ISI Group | Maintains In-Line | $23.00 to $22.00 |
| 15 Sep 2026 | Jefferies | Assumes Hold | $22.00 to $21.00 |
| 31 Aug 2026 | Barclays | Maintains Equal-Weight | $23.00 to $24.00 |
| 13 Aug 2026 | Baird | Maintains Outperform | $21.00 to $24.00 |
| 11 Aug 2026 | Citigroup | Maintains Neutral | $20.00 to $22.00 |
| 10 Aug 2026 | RBC Capital | Maintains Outperform | $21.00 to $24.00 |
| 6 Aug 2026 | Cantor Fitzgerald | Maintains Neutral | $20.00 to $23.00 |
| 15 Jul 2026 | Wells Fargo | Maintains Equal-Weight | $20.00 to $22.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 2 November 2026 after the close for Q3 2026, with EPS expected at $0.43 on revenue of $746.0 million. Healthpeak Properties, Inc. beat the EPS estimate in 7 of its last 7 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q2 2026 | 4 Aug 2026 | $0.44 | $0.46 | +4.55% | $771.6M |
| Q1 2026 | 5 May 2026 | $0.43 | $0.45 | +4.65% | $753.0M |
| Q4 2025 | 2 Feb 2026 | $0.22 | $0.47 | +113.64% | $719.4M |
| Q3 2025 | 23 Oct 2025 | $0.22 | $0.46 | +109.09% | $705.9M |
| Q2 2025 | 24 Jul 2025 | $0.22 | $0.46 | +109.09% | $694.3M |
| Q1 2025 | 24 Apr 2025 | $0.46 | $0.46 | 0.00% | $702.9M |
| Q4 2024 | 3 Feb 2025 | $0.45 | $0.46 | +2.22% | $698.0M |
| Q3 2024 | 24 Oct 2024 | $0.44 | $0.45 | +2.27% | $700.4M |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
For the period ended 31 December 2023, Healthpeak Properties, Inc. reported revenue of $135.5 million and net income of $7.1 million. On a trailing twelve month basis the company shows revenue growth of 3.20%, a gross margin of N.A., an operating margin of N.A. and a return on equity of 1.55%.
Income statement
| Line | Amount |
|---|---|
| Revenue | $135,472,000 |
| Selling, General & Administrative Expenses | $7,623,000 |
| Depreciation & Amortization | $47,536,000 |
| Total Operating Expenses | $128,174,000 |
| Operating Profit | $7,298,000 |
| Interest Expense | $21,514,000 |
| Pre-tax Income | $7,298,000 |
| Net Income | $7,122,000 |
Cash flow
| Line | Amount |
|---|---|
| Cash from Operating Activities | $67,518,000 |
| Stock-based Compensation | $3,386,000 |
| Cash from Investing Activities | -$49,298,000 |
| Cash from Financing Activities | -$57,213,000 |
| Dividends Paid | $54,938,000 |
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $156,779,000 |
| Prepaid Expenses | $10,416,000 |
| Operating Lease Right-of-Use Assets | $226,824,000 |
| Total Assets | $5,155,621,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Long-term Debt | $1,973,037,000 |
| Operating Lease Liabilities, Long-term | $104,844,000 |
| Minority Interest | $122,991,000 |
| Total Liabilities | $2,266,095,000 |
| Common Stock | $2,385,000 |
| Retained Earnings | -$1,061,293,000 |
| Other Accumulated Comprehensive Income | $717,000 |
| Total Stockholders Equity | $2,763,527,000 |
| Total Liability & Stockholders Equity | $5,155,621,000 |
Figures as filed with the SEC for the period ended 31 December 2023, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Assets | 0.38 | 79th | Calculated as the ratio of Short-Term Debt + Long-Term Debt / Total Assets. The higher the ratio, the higher the degree of leverage, and consequently, financial risk |
| Debt/Equity | 0.71 | 69th | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Long Term Debt/Long Term Capital | 0.42 | 52nd | Calculated as Long-Term Debt / (Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | -60.2% | 12th | The Net Income growth rate over the trailing twelve months (TTM) |
| Net Income Pct Growth 3 year CAGR | -13.9% | 30th | The Net Income compound annual growth rate (CAGR) over the past 3 years |
| Net Income Pct Growth 5 year CAGR | -5.6% | 35th | The Net Income compound annual growth rate (CAGR) over the past 5 years |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Operating Cashflow Pct Growth | 5.8% | 49th | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | 5.5% | 52nd | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | 5.6% | 56th | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Return on Assets Pct | 0.9% | 56th | Calculated as the ratio of Net Income / Total Assets. It is an indicator of how efficient the company is at using its assets to generate earnings. |
| Return on Equity Pct | 1.6% | 47th | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
Top Line Growth
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Revenue Pct Growth | 3.2% | 41st | The Revenue (Sales) growth rate over the trailing twelve months (TTM) |
| Revenue Pct Growth 3 year CAGR | 7.5% | 59th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 3 years |
| Revenue Pct Growth 5 year CAGR | 5.2% | 41st | The Revenue (Sales) compound annual growth rate (CAGR) over the past 5 years |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open DOC in FundSpec.
Insider activity
No insider transaction was filed in the last 90 days; the most recent is from 1 March 2024.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 1 Mar 2024 | John T Thomas | Director, President and CEO | Disposal | 261,450 | $11.23 | $2.9M |
| 1 Mar 2024 | John T Thomas | Director, President and CEO | Disposal | 261,450 | $11.23 | $2.9M |
| 1 Mar 2024 | Jeffrey Theiler | EVP - CFO | Disposal | 128,619 | $11.23 | $1.4M |
| 1 Mar 2024 | Jeffrey Theiler | EVP - CFO | Disposal | 128,619 | $11.23 | $1.4M |
| 1 Mar 2024 | Mark D. Theine | EVP - Asset Management | Disposal | 113,802 | $11.23 | $1.3M |
| 1 Mar 2024 | Mark D. Theine | EVP - Asset Management | Disposal | 113,802 | $11.23 | $1.3M |
| 1 Mar 2024 | Del Mar Deeni Taylor | EVP-Chief Investment Officer | Disposal | 113,154 | $11.23 | $1.3M |
| 1 Mar 2024 | Del Mar Deeni Taylor | EVP-Chief Investment Officer | Disposal | 113,154 | $11.23 | $1.3M |
| 1 Mar 2024 | John W. Lucey | Chief Acctg & Admin Officer | Disposal | 74,735 | $11.23 | $839K |
| 1 Mar 2024 | John W. Lucey | Chief Acctg & Admin Officer | Disposal | 74,735 | $11.23 | $839K |
| 1 Mar 2024 | Bradley D. Page | SVP - General Counsel | Disposal | 69,442 | $11.23 | $780K |
| 1 Mar 2024 | Bradley D. Page | SVP - General Counsel | Disposal | 69,442 | $11.23 | $780K |
| 1 Mar 2024 | Laurie P Becker | SVP - Controller | Disposal | 64,255 | $11.23 | $722K |
| 1 Mar 2024 | Laurie P Becker | SVP - Controller | Disposal | 64,255 | $11.23 | $722K |
| 1 Mar 2024 | Daniel M Klein | SVP - Deputy CIO | Disposal | 62,285 | $11.23 | $699K |
Insider filings record what officers and directors did with their own shares. Disposals are often planned sales or tax related, so a pattern across several insiders says more than one filing.
SEC filings
The latest filing is a 10-Q from 5 August 2026.
| Filed | Form | Document |
|---|---|---|
| 5 Aug 2026 | 10-Q | View on sec.gov |
| 6 May 2026 | 10-Q | View on sec.gov |
| 3 Feb 2026 | 10-K | View on sec.gov |
| 24 Oct 2025 | 10-Q | View on sec.gov |
| 25 Jul 2025 | 10-Q | View on sec.gov |
| 25 Apr 2025 | 10-Q | View on sec.gov |
| 4 Feb 2025 | 10-K | View on sec.gov |
| 25 Oct 2024 | 10-Q | View on sec.gov |
| 26 Jul 2024 | 10-Q | View on sec.gov |
| 26 Apr 2024 | 10-Q | View on sec.gov |
Company profile
- Exchange
- NYSE
- Sector
- REITs and Investment Holdings
- Industry
- Trading
- Headquarters
- Irvine, Colorado
- Chief executive
- Scott M. Brinker
- Employees
- 200
- Website
- healthpeak.com
- SEC CIK
- 0000765880
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns and develops high-quality real estate in the three private-pay healthcare asset classes of Life Science, Medical Office and Senior Housing.
Sector and peers
Healthpeak Properties, Inc. is part of the REITs and Investment Holdings sector, which FundSpec tracks across 179 companies.
Companies in the same industry by market capitalization:
AVB AvalonBay Communities Inc.TPL Texas Pacific Land Corp.
Put two of them side by side in Compare.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for DOC are available to subscribers, with the same screen in the iOS and Android apps.
Open DOC in FundSpec